Resverlogix Announces Participation in Upcoming Conferences
CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce the Company’s participation in the following upcoming industry conferences.
| • American Society of Nephrology – ASN 2017 Annual Meeting | |
| Location: | New Orleans, LA. |
| Date: | November 3rd, 2017 |
| Poster 1: |
“Analysis of the Plasma Proteome Reveals Dysregulation of Molecular Pathways in Patients with Stage 4 Chronic Kidney Disease” |
| Presentation Time: | 10:00am - 12:00pm CT |
| Date: | November 4th, 2017 |
| Poster 2: |
“Apabetalone (RVX-208) Impacts Key Markers and Pathways Associated with Chronic Kidney Disease in Patients with Severe Renal Impairment” |
| Presentation Time: |
10:00am - 12:00pm CT |
| Meeting Link: | LINK |
| • BIO-Europe 2017 | |
| Location: | Berlin, Germany. |
| Date: | November 7th, 2017 |
| Presentation Time: | 4:45pm CEST |
| Presenting: | Mr. Donald McCaffrey, President and Chief Executive Officer |
| Conference Link: | LINK |
| • American Heart Association – AHA Scientific Sessions 2017 | |
| Location: | Anaheim, CA |
| Date: | November 13th, 2017 |
| Poster: |
“Apabetalone Downregulates Factors That Promote Vascular Calcification and Contribute to Cardiovascular Events” |
| Presentation Time: | 10:30am PT |
| Meeting Link: | LINK |
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
